June 19, 2018, Vol 319, No. 23, Pages 2349-2450
An Incomplete Prescription – President Trump’s Plan to Address High Drug Prices
Ameet Sarpatwari, JD, PhD; Jerry Avorn, MD; Aaron S. Kesselheim, MD, JD, MPH
JAMA. 2018;319(23):2373-2374. doi:10.1001/jama.2018.7424
This Viewpoint discusses missed opportunities in the 2018 White House blueprint to reduce prescription drug prices, including a proposal that would require CMS to negotiate prices with manufacturers and that would ban unfair practices companies use to extend brand exclusivity.